Drugs / GSK2340269A
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00951041 | Aug 2009 → Aug 2010 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00989287 | Oct 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00968539 | Sep 2009 → Sep 2010 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2340269A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00968539 ↗ |
| Modality | Vaccine | “GSK investigational vaccine GSK2340269A” NCT00951041 ↗ |
| Route | Intramuscular | “Two intramuscular injections” NCT00951041 ↗ |